This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Mejia A , Schulz S , Hyslop T , Weinberg DS , Waldman SA
Molecular staging individualizing cancer management
J Surg Oncol. 2012 Apr 1;105(5) :468-74
PMID: 22441898 PMCID: PMC3312802 URL: https://www.ncbi.nlm.nih.gov/pubmed/22441898
AbstractAlthough the most important prognostic and predictive marker in colorectal cancer is tumor cells in lymph nodes, approximately 30% of patients who are node-negative die from occult metastases. Molecular staging employing specific markers and sensitive detection technologies has emerged as a powerful platform to assess prognosis in node-negative colon cancer. Integrating molecular staging into algorithms that individualize patient management will require validation and the definition of relationships between occult tumor cells, prognosis, and responses to chemotherapy.
NotesMejia, Alex Schulz, Stephanie Hyslop, Terry Weinberg, David S Waldman, Scott A eng R21 CA112147/CA/NCI NIH HHS/ CA75123/CA/NCI NIH HHS/ R01 CA075123-07/CA/NCI NIH HHS/ K30 RR022299-10/RR/NCRR NIH HHS/ R01 CA095026/CA/NCI NIH HHS/ CA95026/CA/NCI NIH HHS/ RC1 CA146033-02/CA/NCI NIH HHS/ R01 CA075123-06/CA/NCI NIH HHS/ R01 CA075123/CA/NCI NIH HHS/ R01 CA095026-06/CA/NCI NIH HHS/ K30 RR022299-09/RR/NCRR NIH HHS/ K30 RR022299/RR/NCRR NIH HHS/ R01 CA095026-05S1/CA/NCI NIH HHS/ T32 GM008562-16/GM/NIGMS NIH HHS/ T32 GM008562/GM/NIGMS NIH HHS/ T32 GM008562-15/GM/NIGMS NIH HHS/ R33 CA112147/CA/NCI NIH HHS/ RC1 CA146033/CA/NCI NIH HHS/ RC1 CA146033-01/CA/NCI NIH HHS/ K30 HL004522/HL/NHLBI NIH HHS/ CA112147/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review J Surg Oncol. 2012 Apr 1;105(5):468-74. doi: 10.1002/jso.21858.